Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 8:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 919 matching trials from the live ClinicalTrials.gov search.
Recruiting No phase listed Observational Accepts healthy volunteers

Kesimpta (Ofatumumab) Pregnancy Registry

NCT05634967
Conditions
Multiple Sclerosis, Pregnancy
Interventions
Kesimpta
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
725 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2033
U.S. locations
1
States / cities
La Jolla, California
Conditions
Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Deficiency, ATP-Binding Cassette Subfamily C Member 6 Deficiency
Interventions
No Intervention for this observational study
Other
Lead sponsor
Inozyme Pharma
Industry
Eligibility
Not listed
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
5
States / cities
Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 2 more
Conditions
Cystic Fibrosis, Hypoestrogenism
Interventions
Transdermal estrogen, Progesterone
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
0 Years to 100 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Pancreatitis, Chronic, Sarcoidosis, VCP Disease, Long COVID, PCD, Symptoms and Signs, Wearables
Interventions
Observational - no intervention
Other
Lead sponsor
4YouandMe
Other
Eligibility
14 Years and older
Enrollment
239 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
New York, New York
Conditions
Hiv
Interventions
Workforce Development (WD) strategies, Quality Management (QM) and Mystery Shopper (MS) Feedback
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2028
U.S. locations
1
States / cities
Tallahassee, Florida
Conditions
Women With ER Positive Breast Cancer Taking (AI) w Joint Discomfort and Stiffness
Interventions
Arm A Directed exercise program, Observation
Other
Lead sponsor
Christiana Care Health Services
Other
Eligibility
40 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Newark, Delaware
Conditions
Total Hip Replacement
Interventions
Not listed
Lead sponsor
Koneksa Health
Industry
Eligibility
30 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
The Villages, Florida
Conditions
COVID-19
Interventions
Laboratory assessment of antibody profiles
Diagnostic Test
Lead sponsor
Aditxt, Inc.
Industry
Eligibility
18 Years and older
Enrollment
403 participants
Timeline
2020 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Endometriosis
Interventions
Observational study, no intervention
Other
Lead sponsor
Aspira Women's Health
Industry
Eligibility
14 Years to 50 Years · Female only
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
10
States / cities
Chandler, Arizona • Burbank, California • Newark, Delaware + 7 more
Conditions
Chronic Pain
Interventions
Cognitive Behavioral Therapy, Chronic Pain Self Management Program, Taper Only
Behavioral · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 85 Years
Enrollment
1,462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Palo Alto, California
Completed Phase 1 Interventional Results available

Inhaled Tobramycin in BPD

NCT04560179
Conditions
Bronchopulmonary Dysplasia
Interventions
Tobramycin solution for inhalation 78mg dose, Tobramycin solution for inhalation 150mg dose, Tobramycin solution for inhalation 216mg dose, Tobramycin solution for inhalation 300mg dose
Drug
Lead sponsor
Erik Allen Jensen
Other
Eligibility
4 Weeks and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
NAFLD
Interventions
somatropin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 29 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Pulmonary Disease, Chronic Obstructive, Lung Diseases, Obstructive
Interventions
blood draw
Other
Lead sponsor
University of Michigan
Other
Eligibility
40 Years to 80 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Carcinoma, Transitional Cell
Interventions
Atezolizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
809 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
41
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 29 more
Conditions
Chronic Pain, Anxiety, Depression, Sleeplessness
Interventions
Nu-V3
Device
Lead sponsor
Nu-Life Solutions
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Schaumburg, Illinois • Greenwood, Indiana
Conditions
Uveitis, Uveitis, Posterior, Uveitis, Anterior, Uveitis, Intermediate, Panuveitis
Interventions
4 mg CLS-TA Suprachoriodal Injection, Sham procedure
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
10
States / cities
Phoenix, Arizona • Mountain View, California • Fort Lauderdale, Florida + 7 more
Conditions
Frailty, Sarcopenia, Sarcopenia in Elderly, Muscle Strength, Post Operative Complications, Nutrition Assessment, Risk Assessment, Elderly (People Aged 65 or More), Hand Strength
Interventions
Frailty assessment, nutrition assessment, cognition assessment, muscle strength testing
Diagnostic Test
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
65 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Age-related Macular Degeneration
Interventions
Ranibizumab 0.5mg
Drug
Lead sponsor
Leonard Feiner, MD, PhD
Other
Eligibility
50 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Teaneck, New Jersey • Vauxhall, New Jersey
Conditions
Hypoparathyroidism
Interventions
No intervention
Other
Lead sponsor
Takeda
Industry
Eligibility
Not listed
Enrollment
1,339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
54
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 42 more
Conditions
Peripheral Arterial Diseases
Interventions
Not listed
Lead sponsor
VA Eastern Colorado Health Care System
Federal
Eligibility
18 Years to 89 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Breast Cancer, Precancerous Condition
Interventions
Ground Flaxseed, No Intervention
Dietary Supplement · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
21 Years to 50 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Chicago, Illinois • Buffalo, New York
Conditions
Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME)
Interventions
ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3, Topical Steroid, ABBV-RGX-314 Dose 4, Aflibercept
Genetic · Drug · Biological
Lead sponsor
AbbVie
Industry
Eligibility
25 Years to 89 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
25
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 21 more
Conditions
Incident Type 2 Diabetes, Incident Obesity
Interventions
No intervention in an observational study
Other
Lead sponsor
Des Moines University
Other
Eligibility
40 Years to 60 Years · Male only
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Des Moines, Iowa
Conditions
Asthma, Allergies
Interventions
Bronchoscopy, Segmental Allergen Challenge and Broncheoalveolar Lavage, PET-CT imaging(13NN perfusion/ventilation, 18FDG inflammation, and CT imaging)
Biological · Procedure
Lead sponsor
Andrew D. Luster, M.D.,Ph.D.
Other
Eligibility
18 Years to 50 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts